Targeted Delivery of Genes to Endothelial Cells and Cell‐ and Gene‐Based Therapy in Pulmonary Vascular Diseases. Issue 4 (22nd October 2013)

• Record Type: Journal Article
• Authors: Suen, Colin M.; Mei, Shirley H.J.; Kugathasan, Lakshmi; Stewart, Duncan J.
• Is Part Of: Comprehensive physiology. Volume 3:Issue 4(2013)
• Page Start: 1749
• Page End: 1779
• Publication Date: 2013-10-22
• DOI: 10.1002/cphy.c120034
• Languages: English
• ISSNs: 2040-4603

Abstract

Abstract: Pulmonary arterial hypertension (PAH) is a devastating disease that, despite significant advances in medical therapies over the last several decades, continues to have an extremely poor prognosis. Gene therapy is a method to deliver therapeutic genes to replace defective or mutant genes or supplement existing cellular processes to modify disease. Over the last few decades, several viral and nonviral methods of gene therapy have been developed for preclinical PAH studies with varying degrees of efficacy. However, these gene delivery methods face challenges of immunogenicity, low transduction rates, and nonspecific targeting which have limited their translation to clinical studies. More recently, the emergence of regenerative approaches using stem and progenitor cells such as endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) have offered a new approach to gene therapy. Cell‐based gene therapy is an approach that augments the therapeutic potential of EPCs and MSCs and may deliver on the promise of reversal of established PAH. These new regenerative approaches have shown tremendous potential in preclinical studies; however, large, rigorously designed clinical studies will be necessary to evaluate clinical efficacy and safety. © 2013 American Physiological Society. Compr Physiol 3:1749‐1779, 2013.